SY
Sreevani Yellavula
About Sreevani Yellavula
Data last updated:
Sreevani Yellavula is a Director at Alfansa Bio Private Limited (since 2017). The companies operate in Pharma and Chemicals. Alfansa Bio Private Limited reported revenue of ₹1.34 Cr (FY 2025). Earlier, Sreevani Yellavula was a Director at Glatrix Biotech Private Limited (2023–2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Alfansa Bio Private Limited U74999TG2017PTC117252 | Director | 22 May 2017 | 2017 | ₹1.34 Cr (FY 2025) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Glatrix Biotech Private Limited U24230TG2022PTC162268 | Director | 25 Jul 2023 | 2022 | ₹18.7 Lakh (FY 2024) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Sreevani Yellavula
| Name | DIN | Company | Designation |
|---|---|---|---|
| Veeraiah Yellavula | 07466546 | Alfansa Bio Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sreevani Yellavula
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sreevani Yellavula
Sreevani Yellavula currently holds 1 directorship: Alfansa Bio Private Limited (Director, since 22 May 2017, revenue ₹1.34 Cr (FY 2025)).
Sreevani Yellavula was first appointed on 22 May 2017 as Director at Alfansa Bio Private Limited. The most recent appointment on record is 25 Jul 2023 at Glatrix Biotech Private Limited.
Sreevani Yellavula held 1 earlier board appointment: Glatrix Biotech Private Limited (Director, 25 Jul 2023 to 29 Jun 2024).
The current boards of Sreevani Yellavula's companies include Veeraiah Yellavula (Alfansa Bio Private Limited).